Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials (2012)

Peer-Reviewed Study · Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. · February 4, 2012

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2012-02-04: Individual-patient-data meta-analysis of 123 randomised trials (about 100,000 women). Adding four cycles of a taxane to a fixed anthracycline regimen cut 8-year breast cancer mortality from 23.9% to 21.1% (absolute 2.8%); the more effective regimens reduced 10-year breast cancer mortality by about one-third relative to no chemotherapy.

8-year breast cancer mortality was 21.1% for the taxane groups versus 23.9% for the control groups (absolute gain 2.8%, SE 0.9; RR 0.86, SE 0.04, 2p=0.0005)

Results (Lancet 379:436 approx.; HTML full text)

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2012-02-04: Individual-patient-data meta-analysis of 123 randomised trials (about 100,000 women). Adding four cycles of a taxane to a fixed anthracycline regimen cut 8-year breast cancer mortality from 23.9% to 21.1% (absolute 2.8%); the more effective regimens reduced 10-year breast cancer mortality by about one-third relative to no chemotherapy. Funders: Cancer Research UK, British Heart Foundation, UK Medical Research Council; the paper states the funders had no role. Individual author disclosures not captured (paywalled PDF; PMC page blocked mid-run). Comparator: no chemotherapy, or a different regimen. Bearing: the 'few percentage points' description fits regimen-versus-regimen comparisons (2.8% absolute at 8 years); it understates chemo versus no chemo, where the paper's own worked example is a 10-year risk falling from 30% to 20% (an absolute 10 points) under a 36% annual death-rate reduction. Study type: review.